Kyoung-Ah Kim1, Pil-Whan Park, Ji-Young Park. 1. Department of Clinical Pharmacology and Toxicology, Anam Hospital, Korea University College of Medicine, 126-1 Anam-dong 5-ga, Sungbuk-gu, Seoul 136-705, Korea.
Abstract
OBJECTIVE: The aim of the present study was to assess whether quercetin exhibited any inhibitory effect on P-glycoprotein (P-gp)-mediated drug disposition in humans usingfexofenadine as a P-gp substrate. METHODS:Twelve healthy subjects were enrolled in the study and treated daily for 7 days with 500 mg quercetin or placebo 3 times a day. On day 7, a single dose of 60 mg fexofenadine was administered orally. Plasma and urinary fexofenadine concentrations were measured, and pharmacokinetic differences between placebo and quercetin phases were assessed. RESULTS: The mean plasma concentrations of fexofenadine were significantly increased after quercetin treatment compared to those of the placebo phase. The area under the time versus concentration curve (AUC) of plasma fexofenadine was increased by 55% by quercetin (2,005.3 versus 3,098.6 ng.h/mL, P < 0.001) and similarly the maximum plasma concentration (C(max)) during the quercetin phase was elevated by 68% compared to that of the placebo phase (295.3 versus 480.3 ng/mL, P = 0.006). Although the oral clearance of fexofenadine was decreased significantly by 37% after quercetin treatment (61.4 versus 38.7 L/h, P < 0.001), no differences in the renal clearance and half-life were observed between placebo and quercetin phases. CONCLUSION: The results of the present study showed that short-term use of quercetin elevated the plasma concentrations of fexofenadine, probably by the inhibition of P-gp-mediated efflux in humans.
RCT Entities:
OBJECTIVE: The aim of the present study was to assess whether quercetin exhibited any inhibitory effect on P-glycoprotein (P-gp)-mediated drug disposition in humans using fexofenadine as a P-gp substrate. METHODS: Twelve healthy subjects were enrolled in the study and treated daily for 7 days with 500 mg quercetin or placebo 3 times a day. On day 7, a single dose of 60 mg fexofenadine was administered orally. Plasma and urinary fexofenadine concentrations were measured, and pharmacokinetic differences between placebo and quercetin phases were assessed. RESULTS: The mean plasma concentrations of fexofenadine were significantly increased after quercetin treatment compared to those of the placebo phase. The area under the time versus concentration curve (AUC) of plasma fexofenadine was increased by 55% by quercetin (2,005.3 versus 3,098.6 ng.h/mL, P < 0.001) and similarly the maximum plasma concentration (C(max)) during the quercetin phase was elevated by 68% compared to that of the placebo phase (295.3 versus 480.3 ng/mL, P = 0.006). Although the oral clearance of fexofenadine was decreased significantly by 37% after quercetin treatment (61.4 versus 38.7 L/h, P < 0.001), no differences in the renal clearance and half-life were observed between placebo and quercetin phases. CONCLUSION: The results of the present study showed that short-term use of quercetin elevated the plasma concentrations of fexofenadine, probably by the inhibition of P-gp-mediated efflux in humans.
Authors: Mikko Niemi; Kari T Kivistö; Ute Hofmann; Matthias Schwab; Michel Eichelbaum; Martin F Fromm Journal: Br J Clin Pharmacol Date: 2005-05 Impact factor: 4.335
Authors: Piwen Wang; Jaydutt V Vadgama; Jonathan W Said; Clara E Magyar; Ngan Doan; David Heber; Susanne M Henning Journal: J Nutr Biochem Date: 2013-10-10 Impact factor: 6.048
Authors: Silke Conen; Eef L Theunissen; Annemiek Vermeeren; Peter van Ruitenbeek; Peter Stiers; Mitul A Mehta; Stefan W Toennes; Johannes G Ramaekers Journal: Psychopharmacology (Berl) Date: 2013-04-07 Impact factor: 4.530
Authors: S Mohana; M Ganesan; B Agilan; R Karthikeyan; G Srithar; R Beaulah Mary; D Ananthakrishnan; D Velmurugan; N Rajendra Prasad; Suresh V Ambudkar Journal: Mol Biosyst Date: 2016-07-19